Natural product inhibitors of the ubiquitin-proteasome pathway

Current Drug Targets

Volumn 12, Issue 11, 2011, Pages 1581-1594

  Schneekloth Jr , John S ^a   Crews, Craig M ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epoxomicin; Inhibitors; Lactacystin; Natural products; Proteasome; Salinosporamide; Ubiquitin; Ubiquitin proteasome pathway

Indexed keywords

BELACTOSIN A; BELACTOSIN C; BORTEZOMIB; CELASTROL; EPONEMYCIN; EPOPROMYCIN A; EPOXOMICIN; FELLUTAMIDE A; FELLUTAMIDE B; KETONE DERIVATIVE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LACTONE DERIVATIVE; NATURAL PRODUCT; PEPTIDE DERIVATIVE; PHYSALIN B; PHYSALIN C; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEIN P53; SALINOSPORAMIDE A; TMC 86A; TMC 89B; TMC 96; TYROPEPTIN A; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHAFERIN A; WITHANOLIDE;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; REVIEW;

BIOLOGICAL AGENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 80054088222     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798109491     Document Type: Review

References (95)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70(3): 461-77.
2. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21(4): 245-73.
3. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 1999; 97(4): 431-4.
4. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5(7): 670-7.
5. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3(1): 20-6.
6. Muratani M, Tansey WR. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4(3): 192-201.
7. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
8. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127(2): 165-72.
9. Adams J, Kauffman M. Development of the proteasome inhihitor Velcade(TM) (Bortezomib). Cancer Invest 2004; 22(2): 304-11.
10. Kim KB, Crews CM. Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. J Med Chem 2008; 51(9): 2600-5.
11. Tsukamoto S, Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 2006; 13(7): 745-54.
12. Tsukamoto S. The search for inhibitors of the ubiquitin-proteasome system from natural resources for drug development. J Nat Med 2006; 60(4): 273-8.
13. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8(8): 739-58.
14. Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets 2009; 10(10): 968-81.
15. [15] Verdoes M, Florea BI, van der Marel GA, Overkleeft HS. Chemical tools to study the proteasome. Eur J Org Chem 2009; (20): 3301-13.
16. Tsukamoto S, Yokosawa H. Targeting the proteasome pathway. Expert Opin Ther Targets 2009; 13(5):605-21.
17. Molineaux CJ, Crews CM. Proteasome inhibitors. Cancer, principles & practice of oncology. Devita VT, Lawrence TS, Rosenberg SA, Eds. 2008; pp. 486-90.
18. Omura S, Fujimoto T, Otoguro K, et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma- cells. J Antibiot 1991; 44(1): 113-6.
19. Omura S, Matsuzaki K, Fujimoto T, et al. Structure of Lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma-cells. J Antibiot 1991; 44(1): 117-8.
20. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino- terminal threonine modification by Lactacystin. Science 1995; 268(5211): 726-31.
21. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL. A Beta-Lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell-line and inhibits cell-cycle progression in an osteosarcoma cell-line. Proc Natl Acad Sci USA 1994; 91(8): 3358-62.
22. Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009; 17(6): 2175-80.
23. Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR, Fenical W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J Org Chem 2005; 70(16): 6196-203.
24. Reed KA, Manam RR, Mitchell SS, et al. Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalino- sporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. J Nat Prod 2007; 70(2): 269-76.
25. Stadler M, Bitzer J, Mayer-Bartschmid A, et al. Cinnabaramides A- G: Analogues of lactacystin and salinosporamide from a terrestrial streptomycete. J Nat Prod 2007; 70(2): 246-52.
26. Asai A, Hasegawa A, Ochiai K, Yamashita Y, Mizukami T. Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J Antibiot 2000; 53(1): 81-3.
27. Groll M, Larionov OV, Huber R, de Meijere A. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation. Proc Natl Acad Sci USA 2006; 103(12): 4576-9.
28. Sugawara K, Hatori M, Nishiyama Y, et al. Eponemycin, a new antibiotic active against B16 melanoma.1. production, isolation, structure and biological activity. J Antibiot 1990; 43(1): 8-18.
29. Tsuchiya K, Kobayashi S, Nishikiori T, Nakagawa T, Tatsuta K. Epopromycins, novel cell wall synthesis inhibitors of plant protoplast produced by Streptomyces sp. NK04000. J Antibiot 1997; 50(3): 261-3.
30. Koguchi Y, Kohno J, Suzuki S, et al. TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094 II. Physico-chemical properties and structure determination. J Antibiot 2000; 53(1): 63-5.
31. Koguchi Y, Nishio M, Suzuki S, Takahashi K, Ohnuki T,Komatsubara S. TMC-89A and B, new proteasome inhibitors from Streptomyces sp. TC 1087. J Antibiot 2000; 53(9): 967-72.
32. Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 1992; 45(11): 1746-52.
33. Groll M, Kim KB, Kairies N, Huber R, Crews CM. The Molecular Basis for the Selectivity of an *,*-epoxyketone proteasome inhibitor revealed by crystal structural analysis of an epoxomicin: 20S proteasome complex. J Am Chem Soc 2000; 122: 1237-8.
34. Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999; 9(15): 2283-8.
35. Kim KB, Myung J, Sin N, Crews CM. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 1999; 9(23): 3335-40.
36. Jagannath S, Vij R, Stewart AK, et al. Phase II study of Carfilzomib in patients with relapsed and refractory multiple myeloma (PX-171-003). Clin Lymphoma Myel 2009; 9: S61.
37. Vij R, Wang M, Orlowski R, et al. Phase II study of Carfilzomib in patients with relapsed myeloma (PX-171-004). Clin Lymphoma Myel 2009; 9: S61-2.
38. Vij R, Wang M, Orlowski R, et al. Phase II study of Carfilzomib (CFZ) in patients with relapsed myeloma (MM) (PX-171-004). Clin Lymphoma Myel 2009; 9: S78.
39. Shigemori H, Wakuri S, Yazawa K, Nakamura T, Sasaki T, Kobayashi J. Fellutamide A and Fellutamide B, cytotoxic peptides from a marine fish-possessing fungus penicillium fellutanum. Tetrahedron 1991; 47(40): 8529-34.
40. Momose S, Sekizawa R, Hashizume H, et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp MK993- dF2 - I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot 2001; 54(12): 997-1003.
41. Momose I, Sekizawa R, Iinuma H, Takeuchi T. Inhibition of proteasome activity by tyropeptin A in PC12 cells. Biosci Biotechnol Biochem 2002; 66(10): 2256-8.
42. Schneekloth JS, Sanders JL, Hines J, Crews CM. Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. Bioorg Med Chem Lett 2006; 16(14): 3855-8.
43. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol 2008; 15(5): 501-12.
44. Yang HJ, Shi GQ, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound withaferin a isolated from Indian Winter Cherry. Mol Pharmacol 2007; 71(2): 426-37.
45. Devi PU, Sharada AC, Solomon FE. In-vivo growth-inhibitory and radiosensitizing effects of withaferin-a on mouse ehrlich ascites- carcinoma. Cancer Lett 1995; 95(1-2): 189-93.
46. Devi PU, Akagi K, Ostapenko V, Tanaka Y, Sugahara T. Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera. Int J Radiat Biol 1996; 69(2): 193-7.
47. Devi PU, Kamath R, Rao BSS. Radioprotective effect of Phyllanthus niruri on mouse chromosomes. Curr Sci 2000; 78(10): 1245-7.
48. Yokota Y, Bargagna-Mohan P, Ravindranath PP, Kim KB, Mohan R. Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett 2006; 16(10): 2603-7.
49. Falsey RR, Marron MT, Gunaherath GMKB, et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2006; 2(1): 33-8.
50. Sen N, Banerjee B, Das BB, et al. Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ 2007; 14(2): 358-67.
51. Bargagna-Mohan P, Ravindranath PP, Mohan R. Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47(9): 4138-45.
52. Tsukamoto S, Tatsuno M, van Soest RWM, Yokosawa H, Ohta T. New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp. J Nat Prod 2003; 66(9): 1181-5.
53. Ausseil F, Samson A, Aussagues Y, et al. High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources. J Biomol Screen 2007; 12(1): 106-16.
54. Vandenberghe I, Creancier L, Vispe S, et al. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA- associated apoptosis. Biochem Pharmacol 2008; 76(4): 453-62.
55. Yang HJ, Chen D, Cui QZC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66(9): 4758-65.
56. Koguchi Y, Kohno J, Nishio M, et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093 - Taxonomy, production, isolation, and biological activities. J Antibiot 2000; 53(2): 105-9.
57. Kohno J, Koguchi Y, Niskio M, et al. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei Sacc. TC 1093. J Org Chem 2000; 65(4): 990-5.
58. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome: TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol 2001; 311(3): 543-8.
59. Tsukamoto S, Koimaru K, Ohta T. Secomycalolide A: a new proteasome inhibitor isolated from a marine sponge of the genus Mycale. Marine Drugs 2005; 3(2): 29-35.
60. Phuwapraisirisan P, Matsunaga S, van Soest RWM, Fusetani N. Isolation of a new mycalolide from the marine sponge Mycale izuensis. J Nat Prod 2002; 65(6): 942-3.
61. Hori M, Saito SY, Shin YZ, Ozaki H, Fusetani N, Karaki H. Mycalolide-B, a novel and specific inhibitor of actomyosin atpase isolated from marine sponge. FEBS Lett 1993; 322(2): 151-4.
62. Fusetani N, Yasumuro K, Matsunaga S, Hashimoto K. Mycalolides-a - C, Hybrid Macrolides of Ulapualides and Halichondramide, from a Sponge of the Genus Mycale. Tetrahedron Lett 1989; 30(21): 2809-12.
63. Matsunaga S, Sugawara T, Fusetani N. Bioactive marine metabolites, 84 - New mycalolides from the marine sponge Mycale magellanica and their interconversion. J Nat Prod 1998; 61(9): 1164-7.
64. Rashid MA, Gustafson KR, Cardellina JH, Boyd MR. Mycalolide- D and Mycalolide-E, new cytotoxic macrolides from a collection of the stony coral Tubasctrea-Faulkneri. J Nat Prod 1995; 58(7): 1120-5.
65. Wäspi U, Blanc D, Winkler T, Ruedi P, Dudler R. Syringolin, a novel peptide elicitor from Pseudomonas syringae pv. Syringae that induces resistance to Pyricularia oryzae in rice. Mol Plant Microbe Interact 1998; 11: 727-33.
66. Oka M, Nishiyama Y, Ohta S, et al. Glidobactins A, B and C, new tumor antibiotics. I. Production, isolation, chemical properties, and biological activity. J Antibiot 1988; 41(10): 1331-7.
67. Groll M, Schellenberg B, Bachmann AS, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008; 452: 755-8.
68. Clerc J, Florea BI, Kraus M, et al. Syringolin A selectively labels the 20S proteasome in murine EL4 in wild-type and bortezomib- adapted leukaemic cell lines. Chembiochem 2009; 10(16): 2638-43.
69. Sekizawa R, Momose I, Kinoshita N, et al. Isolation and structural determination of phepropeptins A, B, C, and D, new proteasome inhibitors, produced by Streptomyces sp. J Antibiot 2001; 54(11): 874-81.
70. Sasse F, Steinmetz H, Schupp T, et al. Argyrins, immunosup- pressive cyclic peptides from myxobacteria - I. Production, isolation, physico-chemical and biological properties. J Antibiot 2002; 55(6): 543-51.
71. Nickeleit I, Zender S, Sasse F, et al. Argyrin A reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008; 14(1): 23-35.
72. Matsuda H, Sato N, Yamazaki M, Naruto S, Kubo M. Testosterone 5 alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma. Biol Pharm Bull 2001; 24(5): 586-7.
73. Camarda L, Merlini L, Nasini G. Dragons blood from dracaena- draco - structure of novel homoisoflavanoids. Heterocycles 1983; 20(1): 39-43.
74. Takasugi M, Anetai M, Masamune T, Shirata A, Takahashi K., Studies on phytoalexins of the Moraceae.5. Broussonin-a and Broussonin-B new phytoalexins from diseased paper mulberry. Chem Lett 1980; (3): 339-40.
75. Tsukamoto S, Wakana T, Koimaru K, Yoshida T, Sato M, Ohta T. 7-Hydroxy-3-(4-hydroxybenzyl)chroman and broussonin B: Neurotrophic compounds, isolated from Anemarrhena asphodeloides BUNGE, function as proteasome inhibitors. Biol Pharm Bull 2005; 28(9): 1798-800.
76. Nam S, Smith DM, Dou QP. Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and bax expression, and induces G(1) arrest and apoptosis. Cancer Epidemiol Biomarkers Prev 2001; 10(10): 1083-8.
77. Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003; 66(6): 965-76.
78. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005; 69(10): 1421-32.
79. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276(16): 13322-30.
80. Pahl HL, Krauss B, SchulzeOsthoff K, et al. The immunosup- pressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappa B. J Exp Med 1996; 183(4): 1829-40
81. Kroll M, Arenzana-Seisdedos F, Bachelerie F, Thomas D, Friguet B, Conconi M. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol 1999; 6(10): 689-98.
82. FigueiredoPereira ME, Chen WE, Li JR, Johdo O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem 1996; 271(28): 16455-9.
83. Ahond A, Zurita MB, Colin M, et al. Girolline, a new antitumoral compound extracted from the sponge, Pseudaxinyssa-Cantharella N-Sp (Axinellidae). CR Acad Sci Paris 1988; 307(2): 145-8.
84. Tsukamoto S, Yamashita K, Tane K, et al. Girolline, an antitumor compound isolated from a sponge, induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53. Biol Pharm Bull 2004; 27(5): 699-701.
85. Sekizawa R, Ikeno S, Nakamura H, et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 2002; 65(10): 1491-3.
86. Tsukamoto S, Hirota H, Imachi M, et al. Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine- derived fungus, Aspergillus sp. Bioorg Med Chem Lett 2005; 15(1): 191-4.
87. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 2001; 276(32): 30366-73.
88. Verbitski SM, Mullally JE, Fitzpatrick FA, Ireland CM. Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity. J Med Chem 2004; 47(8): 2062-70.
89. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408(6810): 307-10.
90. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420(1): 25-7.
91. Isogai A, Washizu M, Kondo K, Murakoshi S, Suzuki A. Isolation and identification of (+)-hexylitaconic acid as a plant-growth regulator. Agricult Biol Chem 1984; 48(10): 2607-9.
92. Tsukamoto S, Yoshida T, Hosono H, Ohta T, Yokosawa H. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorg Med Chem Lett 2006; 16(1): 69-71.
93. Duncan SJ, Gruschow S, Williams DH, et al. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 2001; 123(4): 554-60.
94. Clark RC, Lee SY, Boger DL. Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures. J Am Chem Soc 2008; 130(37): 12355-69.
95. Lee SY, Clark RC, Boger DL. Total synthesis, stereochemical reassignment, and absolute configuration of chlorofusin. J Am Chem Soc 2007; 129(32): 9860.